Trial Profile
A Rapid Pharmacokinetic Trial of the Bioavailability of Four MK-1439 Nano Formulations in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Doravirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 21 Feb 2019 Outcome measures, trial focus, inclusion and exclusion criteria, treatments has been amended.
- 08 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 26 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.